Comparative Pharmacology
Head-to-head clinical analysis: E BASE versus ERYTHROCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E BASE versus ERYTHROCIN STEARATE.
E-BASE vs ERYTHROCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
E-BASE is a proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing gastric acid secretion.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
25 mg orally once daily.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; may be prolonged in renal impairment.
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic